The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...